Key Findings: New Automated Virus Filtration System Targets Gene Therapy Manufacturing
Asahi Kasei Bioprocess has unveiled the VANTIJ® SU-VFC Benchtop, a new benchtop automated single-use virus filtration system, designed to enhance the critical virus removal step in gene therapy drug manufacturing. This system specifically aims to improve efficiency and consistency during laboratory-scale research and process development by eliminating variability inherent in manual operations. This advancement is expected to accelerate the development and ensure stable supply of high-value gene therapies.
Technical and Clinical Details: Compact Design with Advanced Automation and Filter Compatibility
The VANTIJ® SU-VFC Benchtop inherits the high automation and reliability features of the VANTIJ product family, simplifying complex virus filtration processes with minimal operator intervention. Its compact design facilitates easy integration into limited lab spaces, reducing adoption barriers. The system is fully compatible with Asahi Kasei’s renowned Planova™ 35N virus-removal filters, known for their high virus clearance efficiency and excellent protein recovery. This ensures maximum quality and yield of gene therapy vectors, bolstering the foundation for next-generation therapeutic development. The automated process mitigates human error and streamlines traceability and validation in Good Manufacturing Practice (GMP) environments.
Background and Industry Context: Expanding Gene Therapy Market and Manufacturing Challenges
Gene therapy holds immense promise for providing curative solutions to many previously untreatable diseases, including cancers, rare genetic disorders, and infectious diseases. While the market is rapidly expanding, manufacturing complexity, cost, and quality control remain significant challenges. Particularly for gene therapies utilizing viral vectors, efficient virus removal during manufacturing is crucial for patient safety. Traditional manual filtration methods are labor-intensive, time-consuming, and prone to variability. Automated, single-use systems like the VANTIJ® SU-VFC Benchtop are key to overcoming these challenges and accelerating the path to commercial gene therapy production.
Strategic Significance and Outlook: Contributing to Standardization and Efficiency in Gene Therapy Manufacturing
Asahi Kasei Bioprocess aims to seamlessly support the transition from R&D to commercial production for gene therapies with this new benchtop system. Its adoption will be an indispensable tool for standardizing virus filtration processes and reducing risks during manufacturing scale-up. In the long term, this system is expected to promote the broader adoption of automation and single-use technologies across biopharmaceutical manufacturing, thereby improving the speed and efficiency of overall drug development. Asahi Kasei will continue to contribute to advancements in life science through innovation in bioprocessing technology.
Source: https://www.asahi-kasei.com/news/2026/e260915
Get our weekly technology intelligence — free
Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.
Subscribe Free — Weekly Tech Intelligence
By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.
- Your email and selected fields are used only to deliver the newsletter.
- We never share your information with third parties.
- You can unsubscribe anytime via the link in each email.
See our Privacy Policy for details.
Takes about a minute · Unsubscribe anytime
Comments